Acasă › Limfom Burkitt › Massachusetts
Studii clinice pentru Limfom Burkitt în Massachusetts
10 studii pentru Limfom Burkitt caută participanți în Massachusetts.
Orașe în Massachusetts
Text oficial al studiului (în engleză)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
În curs de recrutareFaza 2
366 Days – 46 Years · Toate sexele · Actualizat 2 oct. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 3
Vârste de la 18 la 39 · Toate sexele · Actualizat 2 oct. 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
În curs de recrutareFaza 1/2
6 Months – 25 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT06395103Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- și încă 1
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 13 feb. 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 4 nov. 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Dana Farber Cancer Institute, Boston
În curs de recrutareFaza 1/2
Vârste de la 15 la 50 · Toate sexele · Actualizat 9 sept. 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
În curs de recrutareFaza 2
Vârste de la 1 la 25 · Toate sexele · Actualizat 4 mai 2025 · NCT03509961Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.